Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ICAM1
REST API REST API
Homo sapiens
ICAM1 is differentially expressed in 346 experiments: 144 organism parts: lung, prostate, ... (142 more);, 214 disease states: normal, glioblastoma, ... (212 more);, 109 cell types 479 cell lines 57 compound treatments and 77 other conditions.
Synonyms BB2, CD54
Orthologs Icam1 (Mus musculus)   ICAM1 (Bos taurus)   Icam1 (Rattus norvegicus)   ENSXETG00000022064 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term regulation of cell shape, plasma membrane, regulation of cell adhesion, positive regulation of nitric oxide biosynthetic process, response to copper ion, protein binding, cytokine-mediated signaling pathway, cell-cell adhesion, heterophilic cell-cell adhesion, extracellular space, membrane, response to hypoxia, external side of plasma membrane, response to ionizing radiation, cell adhesion, cell adhesion mediated by integrin, integral to plasma membrane, response to lipopolysaccharide, receptor activity, response to drug, integrin binding, positive regulation of NF-kappaB transcription factor activity, cell surface, cell surface binding, response to ethanol, regulation of immune response, cellular response to glucose stimulus, T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell, cell aging, leukocyte migration, immunological synapse, cellular response to hypoxia, negative regulation of calcium ion transport, virion attachment, binding of host cell surface receptor, cellular response to nutrient levels, T cell antigen processing and presentation, positive regulation of cellular extravasation, cellular response to tumor necrosis factor, ovarian follicle development, interspecies interaction between organisms, response to amino acid stimulus, response to amphetamine, membrane to membrane docking, adhesion to symbiont, leukocyte cell-cell adhesion, response to sulfur dioxide, cellular response to lipopolysaccharide, response to gonadotropin stimulus, cellular response to organic substance, cellular response to interleukin-1, positive regulation of vasoconstriction, interferon-gamma-mediated signaling pathway, regulation of leukocyte mediated cytotoxicity, response to organic cyclic compound, cellular response to alkaloid, transmembrane signaling receptor activity
InterPro Term Ig_sub, ICAM_N, ICAM, ICAM_VCAM_N
UniProt Accession P05362, B4DNT6, E7ESS4, E9PER2
Gene-Disease Assocation PLASMODIUM FALCIPARUM BLOOD INFECTION LEVEL, MALARIA, SUSCEPTIBILITY TO
Search EB-eye ENSG00000090339
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-2549, E-GEOD-7540, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (42 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MTAB-62, E-MEXP-440
SW480
3
E-GEOD-18005, E-MEXP-1014, E-MTAB-37
AGS
2
E-MTAB-37, E-GEOD-15460
DU145
2
E-GEOD-17482, E-GEOD-20089
HT1080
2
E-GEOD-20089, E-MTAB-37
LNCaP
2
E-GEOD-14990, E-GEOD-14464
473 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-3920, E-GEOD-20677, E-TABM-34, E-GEOD-21909, ... (54 experiments)

Factor Value U/D Experiments
adipocyte
2
E-AFMX-5, E-MTAB-25
fibroblast
2
E-GEOD-3204, E-GEOD-3920
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
2
2
E-TABM-145, E-TABM-130
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
103 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-MTAB-62, ... (68 experiments)

Factor Value U/D Experiments
glioblastoma
1
4
E-GEOD-6014, E-GEOD-4290, E-MTAB-62, E-MTAB-37, E-GEOD-4412 ... (5 experiments)
acute promyelocytic leukemia
1
3
E-GEOD-995, E-MTAB-62, E-GEOD-96, E-GEOD-1729
T-cell acute lymphoblastic leukemia
2
E-GEOD-1577, E-MTAB-37
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-62, E-GEOD-2514
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
208 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-2639, E-GEOD-5542, E-GEOD-5741, E-TABM-782, ... (41 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-941, E-MEXP-1335
interferon-gamma
2
E-GEOD-5542, E-GEOD-1432
tumor necrosis factor
2
E-GEOD-2639, E-GEOD-2638
lipopolysaccharide
1
2
E-TABM-868, E-MEXP-1958, E-GEOD-3720
1,2,4-benzenetriol
1
1
E-GEOD-7664
U0126
1
E-GEOD-697
51 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-2034, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Date of sample preparation and hybridisation
studied in E-GEOD-22541

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, ... (7 experiments)

Dfs follow up
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-MEXP-2280, E-TABM-147, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (8 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-GEOD-20115, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5809, E-GEOD-5681, E-GEOD-20540, E-GEOD-837, E-MEXP-1273, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-974, E-MEXP-2069, ... (39 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, ... (10 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-1493, E-GEOD-21750, E-GEOD-17636, ... (10 experiments)

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-2466

Stimulation
studied in E-GEOD-13909, E-GEOD-4883, E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-43, E-GEOD-1561, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Processing time: 0.321 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM